ZBTB42
geneOn this page
Also known as ZNF925
Summary
ZBTB42 (zinc finger and BTB domain containing 42, HGNC:32550) is a protein-coding gene on chromosome 14q32.33, encoding Zinc finger and BTB domain-containing protein 42 (B2RXF5). Transcriptional repressor.
The protein encoded by this gene is a member of the C2H2 zinc finger protein family. This protein is predicted to have a pox virus and zinc finger (POZ) domain at the N-terminus and four zinc finger domains at the C-terminus. In human and mouse, the protein localizes to the nuclei of skeletal muscle cells. Knockdown of this gene in zebrafish results in abnormal skeletal muscle development and myofibrillar disorganization. A novel homozygous variant of the human gene has been associated with lethal congenital contracture syndrome, an autosomal recessive disorder that results in muscle wasting.
Source: NCBI Gene 100128927 — RefSeq curated summary.
At a glance
- Gene–disease (curated): lethal congenital contracture syndrome 6 (Moderate, GenCC)
- GWAS associations: 10
- Clinical variants (ClinVar): 77 total — 1 pathogenic
- Phenotypes (HPO): 8
- MANE Select transcript:
NM_001137601
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:32550 |
| Approved symbol | ZBTB42 |
| Name | zinc finger and BTB domain containing 42 |
| Location | 14q32.33 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | ZNF925 |
| Ensembl gene | ENSG00000179627 |
| Ensembl biotype | protein_coding |
| OMIM | 613915 |
| Entrez | 100128927 |
Gene structure
Transcript identifiers
Ensembl transcripts: 3 — 3 protein_coding
ENST00000342537, ENST00000555360, ENST00000962340
RefSeq mRNA: 2 — MANE Select: NM_001137601
NM_001137601, NM_001370342
CCDS: CCDS45174
Canonical transcript exons
ENST00000342537 — 1 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001213415 | 104801101 | 104804712 |
Expression profiles
Bgee: expression breadth ubiquitous, 163 present calls, max score 83.87.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.9119 / max 49.2911, expressed in 1038 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 141842 | 2.2605 | 1022 |
| 141843 | 0.6514 | 111 |
Top tissues by expression
246 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| parotid gland | UBERON:0001831 | 83.87 | silver quality |
| esophagus squamous epithelium | UBERON:0006920 | 81.18 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 80.37 | gold quality |
| apex of heart | UBERON:0002098 | 78.66 | gold quality |
| body of pancreas | UBERON:0001150 | 78.15 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 77.48 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 77.17 | gold quality |
| gastrocnemius | UBERON:0001388 | 76.76 | gold quality |
| body of stomach | UBERON:0001161 | 75.86 | gold quality |
| muscle of leg | UBERON:0001383 | 75.31 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 75.30 | gold quality |
| pancreas | UBERON:0001264 | 74.67 | gold quality |
| amniotic fluid | UBERON:0000173 | 73.44 | gold quality |
| nasal cavity mucosa | UBERON:0001826 | 73.40 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 73.39 | gold quality |
| stomach | UBERON:0000945 | 73.14 | gold quality |
| gingival epithelium | UBERON:0001949 | 73.14 | gold quality |
| ventricular zone | UBERON:0003053 | 72.92 | gold quality |
| heart left ventricle | UBERON:0002084 | 72.85 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 72.82 | gold quality |
| esophagus mucosa | UBERON:0002469 | 72.67 | gold quality |
| upper arm skin | UBERON:0004263 | 72.57 | gold quality |
| minor salivary gland | UBERON:0001830 | 72.50 | gold quality |
| cardiac ventricle | UBERON:0002082 | 72.46 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 72.15 | gold quality |
| lower lobe of lung | UBERON:0008949 | 72.10 | silver quality |
| hindlimb stylopod muscle | UBERON:0004252 | 72.04 | gold quality |
| right lobe of liver | UBERON:0001114 | 72.00 | gold quality |
| mouth mucosa | UBERON:0003729 | 71.65 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 71.64 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 7.46 |
| E-CURD-89 | no | 79.82 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
57 targeting ZBTB42, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-8485 | 100.00 | 77.57 | 4731 |
| HSA-MIR-4692 | 100.00 | 67.32 | 2066 |
| HSA-MIR-223-3P | 99.99 | 70.14 | 1140 |
| HSA-MIR-3662 | 99.99 | 73.82 | 5684 |
| HSA-MIR-4514 | 99.99 | 67.10 | 1870 |
| HSA-MIR-27A-3P | 99.98 | 72.13 | 2955 |
| HSA-MIR-27B-3P | 99.98 | 72.13 | 2955 |
| HSA-MIR-9985 | 99.98 | 72.11 | 2939 |
| HSA-MIR-4731-5P | 99.89 | 67.23 | 2537 |
| HSA-MIR-4447 | 99.85 | 67.81 | 2900 |
| HSA-MIR-6817-3P | 99.79 | 68.35 | 2126 |
| HSA-MIR-3156-3P | 99.76 | 66.72 | 939 |
| HSA-MIR-6764-5P | 99.75 | 67.89 | 2304 |
| HSA-MIR-1825 | 99.72 | 68.11 | 1089 |
| HSA-MIR-298 | 99.63 | 67.56 | 1916 |
| HSA-MIR-6134 | 99.63 | 65.68 | 1537 |
| HSA-MIR-1260A | 99.61 | 66.67 | 1098 |
| HSA-MIR-1260B | 99.61 | 66.67 | 1098 |
| HSA-MIR-6132 | 99.60 | 65.83 | 1554 |
| HSA-MIR-6836-5P | 99.60 | 65.62 | 1538 |
| HSA-MIR-3136-3P | 99.57 | 66.59 | 781 |
| HSA-MIR-7155-3P | 99.57 | 66.48 | 794 |
| HSA-MIR-4472 | 99.56 | 66.08 | 1478 |
| HSA-MIR-199A-5P | 99.51 | 69.71 | 1107 |
| HSA-MIR-199B-5P | 99.51 | 69.74 | 1098 |
| HSA-MIR-12132 | 99.47 | 68.90 | 1341 |
| HSA-MIR-940 | 99.37 | 66.14 | 2064 |
| HSA-MIR-532-3P | 99.34 | 65.76 | 1195 |
| HSA-MIR-6808-5P | 99.31 | 66.23 | 2150 |
| HSA-MIR-6893-5P | 99.31 | 66.25 | 2119 |
Literature-anchored findings (GeneRIF, showing 2)
- Data show that ZBTB42 protein is expressed in human skeletal muscle and a murine cell line C2C12 myotubes. (PMID:21193930)
- ZBTB42 mutation defines a novel lethal congenital contracture syndrome. (PMID:25055871)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | si:dkey-79d12.4 | ENSDARG00000078018 |
| mus_musculus | Zbtb42 | ENSMUSG00000037638 |
| rattus_norvegicus | Zbtb42 | ENSRNOG00000037562 |
Paralogs (36): ZBTB32 (ENSG00000011590), SNAI2 (ENSG00000019549), PRDM1 (ENSG00000057657), PRDM6 (ENSG00000061455), ZNF76 (ENSG00000065029), PATZ1 (ENSG00000100105), MAZ (ENSG00000103495), ZBTB16 (ENSG00000109906), ZNF451 (ENSG00000112200), ZBTB45 (ENSG00000119574), ZNF410 (ENSG00000119725), SNAI1 (ENSG00000124216), ZNF384 (ENSG00000126746), ZBTB1 (ENSG00000126804), VEZF1 (ENSG00000136451), PRDM14 (ENSG00000147596), ZNF276 (ENSG00000158805), ZNF362 (ENSG00000160094), ZNF653 (ENSG00000161914), ZNF281 (ENSG00000162702), ZNF148 (ENSG00000163848), ZNF143 (ENSG00000166478), HIC2 (ENSG00000169635), PRDM10 (ENSG00000170325), ZNF296 (ENSG00000170684), ZNF692 (ENSG00000171163), ZNF575 (ENSG00000176472), HIC1 (ENSG00000177374), ZBTB18 (ENSG00000179456), ZBTB20 (ENSG00000181722), ZBTB7C (ENSG00000184828), SNAI3 (ENSG00000185669), ZFP91 (ENSG00000186660), MTF1 (ENSG00000188786), SCRT2 (ENSG00000215397), SCRT1 (ENSG00000261678)
Protein
Protein identifiers
Zinc finger and BTB domain-containing protein 42 — B2RXF5 (reviewed: B2RXF5)
All UniProt accessions (1): B2RXF5
UniProt curated annotations — full annotation on UniProt →
Function. Transcriptional repressor. Specifically binds DNA and probably acts by recruiting chromatin remodeling multiprotein complexes.
Subcellular location. Cytoplasm. Nucleus. Nucleoplasm.
Tissue specificity. Expressed in skeletal muscle (at protein level).
Disease relevance. Lethal congenital contracture syndrome 6 (LCCS6) [MIM:616248] A form of lethal congenital contracture syndrome, an autosomal recessive disorder characterized by degeneration of anterior horn neurons, extreme skeletal muscle atrophy and congenital non-progressive joint contractures. The contractures can involve the upper or lower limbs and/or the vertebral column, leading to various degrees of flexion or extension limitations evident at birth. LCCS6 features include severe polyhydramnios and absent stomach, in addition to multiple contracture deformities. The disease is caused by variants affecting the gene represented in this entry.
Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family. ZBTB18 subfamily.
RefSeq proteins (2): NP_001131073, NP_001357271 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000210 | BTB/POZ_dom | Domain |
| IPR011333 | SKP1/BTB/POZ_sf | Homologous_superfamily |
| IPR013087 | Znf_C2H2_type | Domain |
| IPR036236 | Znf_C2H2_sf | Homologous_superfamily |
Pfam: PF00096, PF00651, PF13894
UniProt features (12 total): zinc finger region 4, region of interest 3, chain 1, domain 1, sequence variant 1, sequence conflict 1, compositionally biased region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-B2RXF5-F1 | 50.03 | 0.00 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 87 (showing top):
GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, BILD_E2F3_ONCOGENIC_SIGNATURE, chr14q32, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP, GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_UP, DODD_NASOPHARYNGEAL_CARCINOMA_DN, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, MIR8485, MIR223_3P, GSE11924_TFH_VS_TH2_CD4_TCELL_UP, MIR571, GSE13493_DP_VS_CD4INTCD8POS_THYMOCYTE_UP
GO Biological Process (3): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), muscle organ development (GO:0007517)
GO Molecular Function (5): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)
GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), plasma membrane (GO:0005886)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| regulation of transcription by RNA polymerase II | 2 |
| transcription by RNA polymerase II | 2 |
| cellular anatomical structure | 2 |
| negative regulation of DNA-templated transcription | 1 |
| regulation of DNA-templated transcription | 1 |
| animal organ development | 1 |
| muscle structure development | 1 |
| chromatin | 1 |
| RNA polymerase II transcription regulatory region sequence-specific DNA binding | 1 |
| DNA-binding transcription factor activity | 1 |
| nucleic acid binding | 1 |
| transition metal ion binding | 1 |
| binding | 1 |
| cation binding | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| intracellular anatomical structure | 1 |
| membrane | 1 |
| cell periphery | 1 |
Protein interactions and networks
STRING
374 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ZBTB42 | UTP25 | Q68CQ4 | 479 |
| ZBTB42 | TRERF1 | Q96PN7 | 449 |
| ZBTB42 | SLC26A1 | Q9H2B4 | 419 |
| ZBTB42 | ZG16B | Q96DA0 | 419 |
| ZBTB42 | GNA15 | P30679 | 415 |
| ZBTB42 | CHST2 | Q9Y4C5 | 384 |
| ZBTB42 | AKT1 | P31749 | 376 |
| ZBTB42 | ANKEF1 | Q9NU02 | 370 |
| ZBTB42 | GTPBP10 | A4D1E9 | 321 |
| ZBTB42 | S100PBP | Q96BU1 | 310 |
| ZBTB42 | PGBD1 | Q96JS3 | 309 |
| ZBTB42 | SULF2 | Q8IWU5 | 305 |
| ZBTB42 | GRHL1 | Q9NZI5 | 293 |
| ZBTB42 | SPDEF | O95238 | 292 |
| ZBTB42 | SCGB3A1 | Q96QR1 | 284 |
IntAct
161 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| ZBTB42 | MDFI | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | KRT40 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | GOLGA2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | ZBTB7B | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | MID2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | NCK2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | POLR1C | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | CIDEC | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | RAD51D | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | AIRIM | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | TTC23 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | ZNF330 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | USHBP1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | KCTD9 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | NDOR1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | CTBP2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | BLK | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | MAGOHB | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | OTX1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | OAZ3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | psi-mi:“MI:0915”(physical association) | 0.560 | |
| ZBTB42 | NOC4L | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | FMR1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | CCDC102B | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | GUCD1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | CINP | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | ZBTB16 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | GEM | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | KANK2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZBTB42 | UBASH3A | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (78): ZBTB42 (Affinity Capture-MS), PRMT9 (Affinity Capture-MS), FBXL17 (Affinity Capture-MS), VRK1 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), MID1 (Affinity Capture-MS), ZNF516 (Affinity Capture-MS), CTBP2 (Affinity Capture-MS), ZPR1 (Affinity Capture-MS), GGPS1 (Affinity Capture-MS), ZBTB42 (PCA), ZBTB42 (Affinity Capture-RNA), ZBTB42 (Two-hybrid), ZBTB42 (Two-hybrid), ZBTB42 (Two-hybrid)
ESM2 similar proteins: A0JNJ4, A2APT9, A6NEL2, A6NP61, B1ASB6, B1WBS3, B2RXF5, F6WEQ6, O15015, O43918, O88282, O88286, O95785, P98168, P98169, Q2M3G4, Q2MHN3, Q2QGD7, Q3U1J1, Q3U381, Q497V6, Q5SW24, Q5SXM2, Q6YND2, Q6ZMQ8, Q6ZMY3, Q7TN08, Q7TSX9, Q80SU3, Q80YE4, Q811H0, Q8BG26, Q8BZW2, Q8C8V1, Q8IX07, Q8IY92, Q8N143, Q8N1G0, Q8NC74, Q8TBE0
Diamond homologs: A0JN76, A1L2U9, A1YEX3, A1YPR0, A2AAX3, B1WAZ8, B1WBS3, B1WBU4, B2RXF5, D3ZA50, O14867, O15062, O15156, O15209, O43167, O43298, O43829, O88282, O88939, O93567, O95365, P24278, P41182, P41183, P52739, P97302, P97303, Q08376, Q0IH98, Q0IJ29, Q0P4X6, Q0VCJ6, Q13105, Q14526, Q1H9T6, Q1L8W0, Q2T9Z7, Q3B725, Q3B7N9, Q3SWU4
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
77 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 1 |
| Likely pathogenic | 0 |
| Uncertain significance | 62 |
| Likely benign | 5 |
| Benign | 8 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 815682 | GRCh37/hg19 14q32.33(chr14:104764078-107285437)x1 | Pathogenic |
SpliceAI
192 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 14:104800701:GT:G | donor_loss | 0.9900 |
| 14:104800702:T:G | donor_loss | 0.9900 |
| 14:104800701:G:GG | donor_gain | 0.9700 |
| 14:104801255:C:G | donor_gain | 0.9700 |
| 14:104800698:G:GT | donor_gain | 0.9600 |
| 14:104800698:GAG:G | donor_gain | 0.9600 |
| 14:104800697:GGAG:G | donor_gain | 0.9500 |
| 14:104801175:GCCCA:G | acceptor_loss | 0.9500 |
| 14:104801176:CCCA:C | acceptor_loss | 0.9500 |
| 14:104801177:CCA:C | acceptor_loss | 0.9500 |
| 14:104801178:CAGG:C | acceptor_loss | 0.9500 |
| 14:104801179:A:AT | acceptor_loss | 0.9500 |
| 14:104801072:G:GT | donor_gain | 0.9300 |
| 14:104801072:G:T | donor_gain | 0.9300 |
| 14:104801179:A:AG | acceptor_gain | 0.9200 |
| 14:104801180:G:GG | acceptor_gain | 0.9200 |
| 14:104801046:C:T | donor_gain | 0.8800 |
| 14:104801180:GGT:G | acceptor_gain | 0.8800 |
| 14:104801172:T:A | acceptor_loss | 0.8700 |
| 14:104801357:A:AG | acceptor_gain | 0.8700 |
| 14:104801358:G:GG | acceptor_gain | 0.8700 |
| 14:104801357:AG:A | acceptor_gain | 0.8500 |
| 14:104801358:GG:G | acceptor_gain | 0.8500 |
| 14:104800909:G:GT | donor_gain | 0.8400 |
| 14:104800679:A:T | donor_gain | 0.8200 |
| 14:104801355:ACAG:A | acceptor_gain | 0.8200 |
| 14:104801008:C:G | donor_gain | 0.8000 |
| 14:104801076:T:TA | donor_gain | 0.8000 |
| 14:104800703:GAGC:G | donor_loss | 0.7700 |
| 14:104800923:G:GT | donor_gain | 0.7500 |
AlphaMissense
2707 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 14:104802308:T:C | F371L | 1.000 |
| 14:104802309:T:C | F371S | 1.000 |
| 14:104802310:T:A | F371L | 1.000 |
| 14:104802310:T:G | F371L | 1.000 |
| 14:104802392:T:C | F399L | 1.000 |
| 14:104802394:C:A | F399L | 1.000 |
| 14:104802394:C:G | F399L | 1.000 |
| 14:104802224:T:C | F343L | 0.999 |
| 14:104802226:C:A | F343L | 0.999 |
| 14:104802226:C:G | F343L | 0.999 |
| 14:104802251:C:G | H352D | 0.999 |
| 14:104802287:T:C | C364R | 0.999 |
| 14:104802296:T:C | C367R | 0.999 |
| 14:104802309:T:G | F371C | 0.999 |
| 14:104802371:T:C | C392R | 0.999 |
| 14:104802393:T:C | F399S | 0.999 |
| 14:104802203:T:C | C336R | 0.998 |
| 14:104802225:T:C | F343S | 0.998 |
| 14:104802289:T:G | C364W | 0.998 |
| 14:104802296:T:A | C367S | 0.998 |
| 14:104802297:G:C | C367S | 0.998 |
| 14:104802308:T:A | F371I | 0.998 |
| 14:104802327:T:C | L377P | 0.998 |
| 14:104802335:C:G | H380D | 0.998 |
| 14:104802337:C:A | H380Q | 0.998 |
| 14:104802337:C:G | H380Q | 0.998 |
| 14:104802373:C:G | C392W | 0.998 |
| 14:104802382:T:G | C395W | 0.998 |
| 14:104802083:T:C | C296R | 0.997 |
| 14:104802205:C:G | C336W | 0.997 |
dbSNP variants (sampled 300 via entrez): RS1000065107 (14:104802696 C>A,T), RS1000442977 (14:104801677 C>A,G), RS1000699304 (14:104804368 C>T), RS1000731457 (14:104804598 G>A,T), RS1000896190 (14:104798813 C>T), RS1001199482 (14:104798653 C>G,T), RS1001717649 (14:104800601 C>G,T), RS1001845566 (14:104804446 T>C), RS1002033436 (14:104799359 A>AC), RS1002189007 (14:104804269 C>G,T), RS1002448034 (14:104799622 G>A), RS1003157437 (14:104802915 A>T), RS1003188776 (14:104803238 C>G,T), RS1003894309 (14:104804909 A>T), RS1003994434 (14:104799877 T>C)
Disease associations
OMIM: gene MIM:613915 | disease phenotypes: MIM:616248
GenCC curated gene-disease
| Disease | Classification | Inheritance |
|---|---|---|
| lethal congenital contracture syndrome 6 | Moderate | Autosomal recessive |
Mondo (1): lethal congenital contracture syndrome 6 (MONDO:0014549)
Orphanet (0):
HPO phenotypes
8 total (8 of 8 shown, HPO-id order):
| HPO | Term |
|---|---|
| HP:0000007 | Autosomal recessive inheritance |
| HP:0000256 | Macrocephaly |
| HP:0001558 | Decreased fetal movement |
| HP:0001561 | Polyhydramnios |
| HP:0002803 | Congenital contracture |
| HP:0002804 | Arthrogryposis multiplex congenita |
| HP:0010963 | Absence of stomach bubble on fetal sonography |
| HP:0030674 | Antenatal onset |
GWAS associations
10 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST002223_64 | HDL cholesterol | 1.000000e-08 |
| GCST002899_22 | HDL cholesterol | 8.000000e-09 |
| GCST004232_77 | HDL cholesterol levels | 3.000000e-08 |
| GCST008070_33 | HDL cholesterol levels | 2.000000e-09 |
| GCST008075_103 | HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) | 3.000000e-19 |
| GCST008075_47 | HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) | 7.000000e-14 |
| GCST008084_16 | HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) | 1.000000e-13 |
| GCST008084_228 | HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) | 3.000000e-20 |
| GCST008085_162 | HDL cholesterol levels in current drinkers | 6.000000e-09 |
| GCST008085_25 | HDL cholesterol levels in current drinkers | 2.000000e-12 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004612 | high density lipoprotein cholesterol measurement |
| EFO:0004329 | alcohol drinking |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
PharmGKB variants
1 variants.
| Variant | Genes | Level | Score | #Clin annots | Drugs |
|---|---|---|---|---|---|
| rs3803300 | AKT1, ZBTB42 | 3 | 0.25 | 1 | risperidone |
CTD chemical–gene interactions
25 total (human), top 25 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Cisplatin | affects cotreatment, increases expression, decreases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| GSK-J4 | decreases expression | 1 |
| FR900359 | increases phosphorylation | 1 |
| hydroxyhydroquinone | decreases expression, decreases reaction | 1 |
| zinc chromate | decreases expression, increases abundance | 1 |
| ferrous chloride | decreases expression | 1 |
| 4-aminobenzhydrazide | decreases expression, decreases reaction | 1 |
| S-(1,2-dichlorovinyl)cysteine | affects response to substance, increases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| chromium hexavalent ion | decreases expression, increases abundance | 1 |
| abrine | decreases expression | 1 |
| jinfukang | affects cotreatment, increases expression | 1 |
| Temozolomide | increases expression | 1 |
| Arsenic Trioxide | increases expression | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Benztropine | affects cotreatment, decreases expression | 1 |
| Cuprizone | affects cotreatment, decreases expression | 1 |
| Lipopolysaccharides | affects response to substance, increases expression | 1 |
| Smoke | decreases expression | 1 |
| Thiram | decreases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Urethane | decreases expression | 1 |
| Valproic Acid | increases methylation | 1 |
| 1-Methyl-4-phenylpyridinium | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Associated diseases: lethal congenital contracture syndrome 6
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): lethal congenital contracture syndrome 6